Navigation Links
Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
Date:11/8/2013

KANSAS CITY, Kan., Nov. 8, 2013 /PRNewswire/ -- Stason Pharmaceuticals, Inc. announced today that it is expanding into Kansas City by moving its brand division from Irvine, Calif. to Kansas City, Kan.  A new entity has been developed, KC Specialty Therapeutics LLC, in which the new assets will be placed to focus on research and development of new chemical entities for humans.

"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."

Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.

KC Specialty Therapeutics LLC will locate alongside Stason Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus.  Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.

"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, president and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."

About Stason Pharmaceuticals
Stason Pharmaceuticals entered the commercial generic market in 1994 and today continues to manufacture and market these products through a global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies, and in 2008, Stason launched its Brand Division. Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. http://www.stasonpharma.com/

About KC Specialty Therapeutics LLC
KC Specialty Pharma is focused on the development of new chemical entities in human orphan drug indications for which there is no available treatment.  Orphan drugs are defined as those that treat less than 200,000 in the US. 

About Greater Kansas City
Home to 2.5 million people, the Kansas City region offers the benefits of more than 50 unique communities and 18 counties in Kansas and Missouri.  www.thinkKC.com


'/>"/>
SOURCE Kansas City Area Development Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
4. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
6. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
7. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
8. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
9. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Research and Markets has announced the addition of ... report to their offering. ... Dermatological conditions are one of the ... the US population suffers from at least one active skin ... market has remained saturated with established and generic products. However, ...
(Date:2/22/2017)... , Feb. 22, 2017   Protein Sciences Corporation ... Flublok® Influenza Vaccine , announced today that they ... Influenza Vaccine Introduction (PIVI) and the Mongolian Ministry of ... of the flu.  The doses of Flublok have been ... Mongolia for health care workers, pregnant women, ...
(Date:2/22/2017)... February 22, 2017 A research report by ... America and the continuously changing landscape of the legal ... in the North America , a 30% increase ... to $21.6 billion by the year 2021 representing a 26 percent ... the United States and Canada ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 2017 , ... Doctors on Liens is continuing its steady expansion of medical ... practicing at North Valley Eye Medical Group in Mission Hills . Eye injuries ... personal injury cases. These injuries have a major impact on the quality of ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... country today, as organizations, advocates, and individuals join together to increase recognition about ... to ultimately save lives. , “Today we mark a nationwide movement to raise ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers ... to help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare ... Access and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, ...
(Date:2/22/2017)... ... 22, 2017 , ... Bellus Medical, a leader in medical ... delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians in ... synthesis and provide a faster and more efficient healing process. There are many ...
Breaking Medicine News(10 mins):